Search
Tapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalTapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake. … [L47291] Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol, PHENOL, 3-((1R,2R)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL)-Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE® TABLETAS 25 MG, REVOLADE ® TABLETAS 50 MGDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. … , resulting in a premature termination of the trial.
Categories: Heterocyclic Compounds, 2-RingProducts: DORVAK®, DORIPURE® 500Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalVernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: (3R)-1-((1R,2R)-2-(2-(3,4-dimethoxyphenyl)ethoxy)cyclohexyl)pyrrolidin-3-olNalmefene
go.drugbank.com/drugs/DB06230ApprovedInvestigationalWithdrawn[L40684] It acts as an antagonist at the mu (μ)-opioid and delta (δ)-opioid receptors and a partial agonist at the kappa (κ)-opioid receptor. … Nalmefene, a 6-methylene analogue of [naltrexone], is an opioid receptor antagonist.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: MORPHINAN-3,14-DIOL, 17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-6-METHYLENE-, (5.ALPHA.)-, 17-(Cyclopropylmethyl)-4,5α-epoxy-6-methylenemorphinan-3,14-diolEflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawnEflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. … [A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or interacts with ras, both very well-known oncogenes, thus increasing the interest in targeting ornithine carboxylase as a
Synonyms: (RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid, 2-(difluoromethyl)ornithineDapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. … [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.
Mixtures: XIGLIF-M, PLEMTUM-MCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesElotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalElotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. … Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.
Elinogrel
go.drugbank.com/drugs/DB06350InvestigationalA P2Y12 inhibitor and platelet aggregation inhibitor.
Categories: Heterocyclic Compounds, 2-Ring